It has recently been shown that XPO1 inhibition, in addition to being directly cytotoxic, downregulates HLA-E expression on malignant B cells and promotes NKG2A+ NK cell activation against lymphoma cells [96]. The gene discussed is KLRC1; the disease is lymphoma.